Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.78 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.78 |
| ▸ | MELK | Q14680 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031150 | 0.88 | HDAC6 (0.81) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24030795 | 0.88 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24031144 | 0.87 | HDAC6 (1.00) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24031073 | 0.86 | HDAC6 (1.00) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24031061 | 0.86 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24030782 | 0.85 | HDAC6 (0.81) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL30159220 | 0.85 | HDAC1 (0.78) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24031158 | 0.85 | HDAC6 (0.88) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24030750 | 0.85 | HDAC6 (1.00) | HDAC1HDAC6HDAC8HDAC11MELK | |
| SCHEMBL24031113 | 0.85 | HDAC6 (0.92) | HDAC1HDAC6HDAC8HDAC11MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110621317-A | Histone Deacetylase (HDACS) inhibitors | 安基生技新药股份有限公司 | 2019-12-27 | — | — | CN | claimed |
| CN-110621317-B | Inhibitors of Histone Deacetylase (HDACS) | 安基生技新药股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11535598-B2 | Histone deacetylases (HDACs) inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2022-12-27 | — | — | US | disclosed |
| US-11535598-B2 | Histone deacetylases (HDACs) inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2022-12-27 | — | — | US | disclosed |
| EP-3624804-B1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | ANNJI PHARM CO LTD (TW) | 2022-02-16 | — | — | EP | disclosed |
| US-20210355089-A1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2021-11-18 | — | — | US | disclosed |
| CN-110621317-A | Histone Deacetylase (HDACS) inhibitors | 安基生技新药股份有限公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535598-B2 | Histone deacetylases (HDACs) inhibitors | HDAC1, HDAC3, HDAC2 | HDAC1 1/4885HDAC6 11/4885HDAC8 6/4885 |
| US-20210355089-A1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | HDAC1, HDAC3, HDAC2 | HDAC1 1/4885HDAC6 8/4885HDAC8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.